Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $17.56.

ATEC has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. Needham & Company LLC increased their price objective on shares of Alphatec from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Finally, Barclays increased their price objective on shares of Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday.

Alphatec Trading Up 2.5 %

ATEC stock traded up $0.29 on Thursday, hitting $11.67. 1,276,798 shares of the company were exchanged, compared to its average volume of 1,852,914. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The business's fifty day moving average is $9.80 and its two-hundred day moving average is $8.08. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -9.12 and a beta of 1.41.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at $5,379,750.81. This represents a 10.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Patrick Miles sold 6,687 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the transaction, the chief executive officer now owns 5,501,715 shares in the company, valued at $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,208 shares of company stock worth $706,835 in the last ninety days. 22.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Lighthouse Investment Partners LLC lifted its position in shares of Alphatec by 257.5% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company's stock worth $2,180,000 after buying an additional 150,244 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after acquiring an additional 297,850 shares during the last quarter. Barclays PLC boosted its stake in Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after acquiring an additional 133,653 shares during the period. Franklin Resources Inc. grew its holdings in shares of Alphatec by 299.3% during the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock valued at $343,000 after purchasing an additional 48,308 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Alphatec during the 3rd quarter worth approximately $2,057,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.